Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Scripps Institute says Illumina infringes on patent
The most prestigious nonprofit sues the most successful biotech
DNA sequencing trace
San Diego's Illumina is a biotech powerhouse. As researchers increasingly discover that genetic factors are the causes of diseases, Illumina stands out: it has an overwhelming share of the market for machines that can sequence an entire genome.
Yesterday (March 18) the stock closed at $150.24, up more than 2 percent. The publication Barron's says this weekend (March 19) that Illumina shares could rise 50 percent because of its solid position.
Barron's raves that in the next decade, "your doctor will prescribe a medicine that is customized specifically for you." The doctor will have a laptop that contains your entire genome. The instrument will probably be supplied by Illumina, which currently has a 70 percent share of the gene-sequencing market.
Scripps Research Institute is one of the world's most prestigious nonprofit research organization specializing in medical research. Indeed, Scripps and Illumina are two shining lights of San Diego–based research. Now, a major battle between the two seems on the horizon.
On March 17, Scripps filed a lawsuit in federal court in San Diego against Illumina, charging patent infringement. Scripps has patented a technology pertaining to a "bifunctional molecule" used in the manufacture of DNA microarrays, according to the suit. These DNA microarrays are used in genetic analyses of many diseases.
"For a number of years, Illumina has manufactured and marketed DNA microarray technologies and products," says the suit. "The bifunctional molecule used in the manufacture of such Illumina products utilizes the Scripps Research Institute's patented technology."
The suit charges that "Illumina has directly infringed" on parts of a patent developed by Scripps scientists. The suit charges that Illumina had knowledge of Scripps's patent when it was using it. The infringement was "deliberate and willful," says the suit.
Illumina refuses to discuss the suit. Scripps did not respond to questions about the suit.
Here's something you might be interested in.
Scripps Institute says Illumina infringes on patent
The most prestigious nonprofit sues the most successful biotech
Scripps Institute says Illumina infringes on patent
The most prestigious nonprofit sues the most successful biotech
DNA sequencing trace
San Diego's Illumina is a biotech powerhouse. As researchers increasingly discover that genetic factors are the causes of diseases, Illumina stands out: it has an overwhelming share of the market for machines that can sequence an entire genome.
Yesterday (March 18) the stock closed at $150.24, up more than 2 percent. The publication Barron's says this weekend (March 19) that Illumina shares could rise 50 percent because of its solid position.
Barron's raves that in the next decade, "your doctor will prescribe a medicine that is customized specifically for you." The doctor will have a laptop that contains your entire genome. The instrument will probably be supplied by Illumina, which currently has a 70 percent share of the gene-sequencing market.
Scripps Research Institute is one of the world's most prestigious nonprofit research organization specializing in medical research. Indeed, Scripps and Illumina are two shining lights of San Diego–based research. Now, a major battle between the two seems on the horizon.
On March 17, Scripps filed a lawsuit in federal court in San Diego against Illumina, charging patent infringement. Scripps has patented a technology pertaining to a "bifunctional molecule" used in the manufacture of DNA microarrays, according to the suit. These DNA microarrays are used in genetic analyses of many diseases.
"For a number of years, Illumina has manufactured and marketed DNA microarray technologies and products," says the suit. "The bifunctional molecule used in the manufacture of such Illumina products utilizes the Scripps Research Institute's patented technology."
The suit charges that "Illumina has directly infringed" on parts of a patent developed by Scripps scientists. The suit charges that Illumina had knowledge of Scripps's patent when it was using it. The infringement was "deliberate and willful," says the suit.
Illumina refuses to discuss the suit. Scripps did not respond to questions about the suit.
Comments